Sign in
Taking people in United StatesPhase 1

Tests RO7656594 safety in advanced prostate cancer

Tests the drug RO7656594 for safety in adults with advanced prostate cancer.

Key facts

Who runs it
Genentech, Inc.
Where
Chicago, Nashville, New Haven, Orlando, and Scottsdale, United StatesSee the 5 sitesAlso in 6 other countries, 21 sites
Registry title
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 1
People taking part
210 people, planned
Started
2 May 2023
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groups
Treatments tested
  • RO7656594
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread. They must already have had certain earlier treatments. The trial tests the safety and early activity of a new drug, RO7656594.

Age
18 years or older
Sex
Men only
Disease stage
Metastatic prostate adenocarcinoma, without small-cell carcinoma or neuroendocrine features. ECOG performance status of 1 or lower.
Earlier treatment
Must have had a second-generation androgen receptor (AR)-targeted therapy such as abiraterone, enzalutamide, apalutamide or darolutamide. Must have had a taxane regimen, or be considered ineligible for one, or have refused one. With a known BRCA1 or BRCA2 mutation: must have had a PARP inhibitor, or be considered ineligible for one, if approved and available.
Biomarker or test result
No specific marker is required. People with a known pathogenic BRCA1 or BRCA2 mutation have an extra treatment condition.

Main reasons for not taking part

  • Approved cancer drug treatment within 14 days or 5 drug half-lives (whichever is longer, up to 28 days) before the first study treatment
  • Any investigational agent within 28 days before the first study treatment
  • Any previous AR protein degrader treatment
  • Untreated central nervous system (CNS) metastases or leptomeningeal disease

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine features
  • Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide)
  • Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regimen, unless otherwise specified
  • For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2 mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor, if such therapy is approved and available

Who cannot take part

  • Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives (whichever is longer, not to exceed 28 days) prior to the first study treatment
  • Treatment with any investigational agent within 28 days prior to the first study treatment
  • Treatment with any previous AR protein degrader
  • Untreated central nervous system (CNS) metastases or leptomeningeal disease; Note: Other protocol specified inclusion/exclusion criteria may apply

Where in United States

Also in 6 other countries, 21 sites

  • University of Illinois Hospital & Health Sciences SystemChicago, United StatesTaking people
  • SCRI Oncology PartnersNashville, United StatesTaking people
  • Yale Cancer CenterNew Haven, United StatesTaking people
  • Sarah Cannon Research Institute @ Florida CancerOrlando, United StatesTaking people
  • HonorHealthScottsdale, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

The 2 groups in the trial

  • Stage 1: Dose EscalationTreatment being tested

    Participants will receive RO7656594 administered at a specified dose on specific days in each 28-day cycle. The dose will be increased in successive cohorts until a study-specific threshold is reached.

    Treatment: RO7656594

  • Stage 2: ExpansionTreatment being tested

    Participants will receive RO7656594 at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD).

    Treatment: RO7656594

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Plain-language title
Tests RO7656594 safety in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 November 2026